Incidence and clinical significance of 491 known fusion genes in a large cohort of Japanese patients with colorectal cancer

• Published in: International journal of clinical oncology 2023-06, Vol.28 (6), p.785-793
• Main Authors: Nanishi, Kenji, Hino, Hitoshi, Hatakeyama, Keiichi, Shiomi, Akio, Kagawa, Hiroyasu, Manabe, Shoichi, Yamaoka, Yusuke, Nagashima, Takeshi, Ohshima, Keiichi, Urakami, Kenichi, Akiyama, Yasuto, Yamaguchi, Ken
• Format: Article
• Language: English
• Subjects: Adenomatous polyposis coli; Cancer; Cancer Research; Clinical significance; Colorectal cancer; Colorectal carcinoma; Fusion protein; Medicine; Medicine & Public Health; Metastases; Oncology; Original Article; Surgical Oncology
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-023-02335-9

Background The clinical significance of fusion genes in colorectal cancer remains unclear. The purpose of this study was to determine the incidence of fusion genes in colorectal cancer and explore their clinical significance by screening for common fusion genes in a large Japanese cohort. Methods This study involved 1588 patients. The incidence of 491 fusion genes was examined using a designed fusion panel. In addition, the patients were classified into two groups ( RSPO fusion-positive or -negative) according to the presence of RSPO fusions, and the clinicopathological and genetic characteristics of both groups were compared. Long-term outcomes were analyzed in patients without distant metastases. Results Fusion genes were detected in 2% (31/1588) of colorectal cancers. The incidence of RSPO fusions (such as PTPRK-RSPO3 and EIF3E-RSPO2 ) was 1.5% (24/1588), making them the most common fusions, whereas the incidence of other fusion genes was extremely low. The distribution of consensus molecular subtypes and frequency of APC mutations were significantly different between the RSPO fusion-positive and -negative groups. The 3-year cumulative incidence rate of recurrence was higher in the RSPO fusion-positive group than in the RSPO fusion-negative group (positive, 31.2% vs. negative, 13.5%, hazard ratio = 2.357; p  = 0.040). Conclusion Broad screening for fusion genes showed that RSPO fusions were the most common in colorectal cancer, with an incidence of 1.5%. RSPO fusions may be clinically significant in identifying patients at a high risk of recurrence who would be responsive to specific treatments.